致死性前列腺癌的诊断特征
基于丹麦前列腺癌登记处的全国性人群研究纳入1995至2013年死于前列腺癌的全部19,487例男性,分析诊断时年龄、PSA、临床分期、Gleason评分及中位生存的趋势。诊断时转移性、局部进展/淋巴结阳性及局限性疾病分别占46.9%、16.8%和36.3%;转移性疾病比例从54.0%降至38.3%,中位生存从1.88年增至3.99年。
要点
- 死于前列腺癌的男性诊断时多数已为局部进展/淋巴结阳性或转移性疾病。
- 诊断时转移性疾病比例从54.0%降至38.3%,局部进展/淋巴结阳性比例从8.6%升至27.3%。
- 中位生存从1995年的1.88年增至2013年的3.99年。
核心结论
- 大型人群研究证实,最终死于前列腺癌的男性多数在诊断时已为局部进展/淋巴结阳性或转移性疾病。
- 诊断时转移性疾病比例随时间显著下降,中位生存平行增加,提示领先时间效应对生存的影响,但目前尚不足以降低前列腺癌特异性死亡率。
研究设计与样本
- 基于丹麦前列腺癌登记处的全国性人群研究,纳入1995至2013年丹麦全部19,487例死于前列腺癌的男性。
- 分析中位生存趋势及诊断时年龄、前列腺特异性抗原、临床分期和Gleason评分的趋势。
主要发现
- 诊断时转移性、局部进展/淋巴结阳性及局限性疾病分别占46.9%、16.8%和36.3%。
- 仅0.15%为局限性疾病且Gleason评分≤6且PSA<10。
- 诊断时转移性疾病比例从54.0%降至38.3%(p<0.0001),局部进展/淋巴结阳性比例从8.6%升至27.3%(p<0.0001)。
- 局限性疾病比例维持在33.2%至41.9%之间。
- 中位生存从1995年的1.88年(95%CI:1.68-2.08)增至2013年的3.99年(95%CI:3.71-4.28),p<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnostic characteristics of men who eventually die from prostate cancer (PCa) and the extent to which early diagnostic strategies have affected these characteristics are unclear. We aimed to investigate trends in survival and clinical presentation at diagnosis in men who eventually died from PCa. PATIENTS AND METHODS: Based on the national database, the Danish Prostate Cancer Registry, a nationwide population-based study of all 19,487 men who died from PCa in Denmark between 1995 and 2013 was conducted. Trends in median survival and trends in age, prostate-specific antigen (PSA), clinical stage, and Gleason score (GS) at diagnosis were analysed. RESULTS: A total of 46.9%, 16.8%, and 36.3% had metastatic (M+), locally advanced/lymph node positive (LaN+), and localised disease, respectively, at diagnosis. Only 0.15% had localised disease, GS ≤ 6 and PSA<10. Over time, the proportion of men with M+ disease at diagnosis decreased from 54.0-38.3% (p < 0.0001), whereas the proportion LaN + disease increased from 8.6-27.3% (p < 0.0001). The proportion of localised disease remained stable at 33.2-41.9%. Median survival increased 2.11 years from 1.88 (95% CI: 1.68-2.08) in 1995 to 3.99 (95% CI: 3.71-4.28) years in 2013, p < 0.0001. CONCLUSIONS: In a large population-based study, the results confirmed concurrent literature that the majority of men who eventually died from PCa had LaN+ or M+ disease at diagnosis. The proportion of men with M+ disease at diagnosis decreased significantly over time, parallelled by an increase in median survival. Taken together, this indicates a lead-time effect on survival, which presently, however, is not substantial enough to result in a reduced PCa-specific mortality.
引用
- Helgstrand JT, Røder MA, Klemann N, et al. Diagnostic characteristics of lethal prostate cancer. Eur J Cancer. 2017. PMID: 28779631. doi:10.1016/j.ejca.2017.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。